Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The use of doublets vs triplets for FLT3-mutated AML

Eunice Wang • 29 Sep 2022
SOHO 2022
Acute Myeloid Leukemia Leukemia Azacitidine Venetoclax

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the need to improve treatment options for patients with FLT3-mutated acute myeloid leukemia (AML). Dr Wang discusses the growing promise of doublet and triplet combination approaches for these patients, and highlights the importance of further investigating their place in the AML treatment landscape. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eunice Wang

2:49
Results of a Phase I trial investigating CYNK-001, a placental NK-cell product, in patients with AML
Eunice Wang • 10 Dec 2023
1:30
A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AML
Eunice Wang • 10 Dec 2023
3:03
The effect of BMI on survival outcomes in adolescents and young adults with AML
Eunice Wang • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals